

41

1648

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 21, 2003

Signature: *[Handwritten Signature]*  
(Sharon M. Sinitich)

Docket No.: 28335/37036US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Kunal Saha

Application No.: 10/040,802

Group Art Unit: 1648

Filed: December 28, 2001

Examiner: J. Stucker

For: METHODS AND MATERIALS RELATING  
TO CD8-TROPIC HIV-1

**RECEIVED**

OCT 29 2003

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Applicants request that the documents listed on the attached Form PTO/SB/08A be made of official record in the above-identified application and considered by the Examiner during examination of the above-identified patent application. Copies of all documents (B1 and C1-C15) are submitted herewith.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

This Information Disclosure Statement has been filed prior to receipt of a first Office Action on the merits, and consequently should be considered by the Patent Office without payment of a fee according to 37 C.F.R. §1.97(b)(3). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855.

Dated: October 21, 2003

Respectfully submitted,

By

  
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/040,802		
		Filing Date	December 28, 2004		
		First Named Inventor	Kunal Saha		
		Art Unit	1648		
		Examiner Name	J. Stucker		
Sheet	1	of	2	Attorney Docket Number	28335/37036 US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	B1	WO 00/71561		11/30/00	Hoxie et al.		
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	CULLEN, A New Entry Route for HIV, <i>Nature Medicine</i> , 7: 20-21 (2001).	
	C2	DUMONCEAUX et al., Spontaneous Mutations in the <i>env</i> Gene of the Human Immunodeficiency Virus Type 1 NDK Isolate are Associated with a CD4-Independent Entry Phenotype, <i>Journal of Virology</i> , 72: 512-19 (1998).	
	C3	FLAMAND et al., Activation of CD8 <sup>+</sup> T Lymphocytes through the T Cell Receptor turns on CD4 Gene Expression: Implications for HIV Pathogenesis, <i>Proc. Natl. Acad. Sci. USA</i> , 95: 3111-3116 (1998).	
	C4	HOFFMAN et al., HIV Type I Envelope Determinants for use of the CCR2b, CCR3, STRL33, and APJ Coreceptors, <i>Proc. Natl. Acad. Sci. USA</i> , 95: 11360-11365 (1998).	
	C5	HUANG et al., Construction and Characterization of a Temperature-Sensitive Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutant, <i>Journal of Virology</i> , 72: 2047-2054 (1998).	
	C6	KANEKO et al., Human Immunodeficiency Virus Type 2 Envelope Glycoprotein Binds to CD8 as Well as to CD4 Molecules on Human T Cells, <i>Journal of Virology</i> , 71: 8918-922 (1997).	
	C7	KITCHEN et al., Costimulation of Naïve CD8 <sup>+</sup> Lymphocytes Induces CD4 Expression and Allows Human Immunodeficiency Virus Type 1 Infection, <i>Journal of Virology</i> , 72: 9054-9060 (1998).	
	C8	KOLCHINSKY et al., Adaptation of a CCR5-Using, Primary Human Immunodeficiency Virus Type 1 Isolate for CD4-Independent Replication, <i>Journal of Virology</i> , 73: 8120-8126 (1999).	



PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/040,802		
		Filing Date	December 28, 2004		
		First Named Inventor	Kunal Saha		
		Group Art Unit	1648		
		Examiner Name	J. Stucker		
Sheet	2	of	2	Attorney Docket Number	28335/37036 US
C9	LIVINGSTONE et al., Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1, <i>Lancet</i> , 348: 649-654 (1996).				
C10	SAHA et al., Generation of CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri, <i>Nature Medicine</i> , 2:1272-1275 (1996).				
C11	SAHA et al., Endogenous Production of $\beta$ -Chemokines by CD4 <sup>+</sup> , but Not CD8 <sup>+</sup> , T-Cell Clones Correlates with the Clinical State of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and May Be Responsible for Blocking Infection with Non-Syncytium-Inducing HIV-1 In Vitro, <i>Journal of Virology</i> , 72: 876-881 (1998).				
C12	SAHA et al., Isolation of primary HIV-1 that target CD8 <sup>+</sup> T Lymphocytes using CD8 as a receptor, <i>Nature Medicine</i> , 7: 65-72 (2001).				
C13	SAHA et al., Evidence of Productively Infected CD8 <sup>+</sup> T Cells in Patients With AIDS: Implications for HIV-1 Pathogenesis, <i>Journal of Acquired Immune Deficiency Syndromes</i> , 26: 199-207 (2001).				
C14	SEMENZATO et al., CD8 <sup>+</sup> T Lymphocytes in the Lung of Acquired Immunodeficiency Syndrome Patients Harbor Human Immunodeficiency Virus Type 1, <i>Blood</i> , 85: 2308-2314 (1995).				
C15	SHANKARAPPA et al., Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection, <i>Journal of Virology</i> , 73: 10489-10502 (1999).				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.